Prospective Assessment of CYP2D6 by Genotyping, Phenotyping and Measurement of Tamoxifen, 4-Hydroxy-Tamoxifen and Endoxifen in Breast Cancer Patients Treated with Tamoxifen

被引：0
|
作者：
Zaman, K.
Dahmane, E.
Csajka, C.
Perey, L.
Buclin, T.
Bodmer, A.
Leyvraz, S.
Rindisbacher, M. Galmiche
Berthod, G.
Chin, E.
Decosterd, L.
机构：
[1] Univ Hosp CHUV, CePO, Lausanne, Switzerland
[2] Univ Hosp CHUV, Clin Pharmacol, Lausanne, Switzerland
[3] Univ Lausanne Hosp, Ctr Psychiat Neurosci, Lausanne, Switzerland
[4] Univ Hosp HUG, Med Oncol, Geneva, Switzerland
[5] Hosp Morges, Med Oncol, Morges, Switzerland
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-PD05-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD05-09
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Berry, Donald
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17): : 1267 - 1269
  • [2] Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
    Schroth, Werner
    Winter, Stefan
    Muerdter, Thomas
    Schaeffeler, Elke
    Eccles, Diana
    Eccles, Bryony
    Chowbay, Balram
    Khor, Chiea C.
    Tfayli, Arafat
    Zgheib, Nathalie K.
    Eichelbaum, Michel
    Schwab, Matthias
    Brauch, Hiltrud
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [3] Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
    Lee, Clara Inkyung
    Low, Siew Kee
    Maldonado, Ricardo
    Fox, Peter
    Balakrishnar, Bavanthi
    Coulter, Sally
    de Bruijn, Peter
    Koolen, Stijn L. W.
    Gao, Bo
    Lynch, Jodi
    Zdenkowski, Nicholas
    Hui, Rina
    Liddle, Christopher
    Mathijssen, Ron H. J.
    Wilcken, Nicholas
    Wong, Mark
    Gurney, Howard
    BREAST, 2020, 54 : 229 - 234
  • [4] CYP2D6 GENOTYPING TO GUIDE USE OF TAMOXIFEN IN BREAST CANCER
    Irvin, William J., Jr.
    Weck, Karen E.
    Walko, Christine M.
    Ibrahim, Joseph G.
    Chiu, Wing. K.
    Dees, E. Claire
    Ogburn, Evan T.
    Desta, Zeruesenay
    Flockhart, David A.
    McLeod, Howard L.
    Evans, James P.
    Carey, Lisa A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S88 - S88
  • [5] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Province, Michael A.
    Klein, Teri E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [6] The Impact of CYP2D6*4 on the Survival of Tamoxifen Treated Breast Cancer Patients
    Al Matrafi, Abdullah
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1345 - 1346
  • [7] Optimized CYP2D6 phenotype assignment for plasma endoxifen prediction in breast cancer patients treated with tamoxifen
    Schroth, Werner
    Winter, Stefan
    Eichelbaum, Michel
    Muerdter, Thomas
    Schwab, Matthias
    Brauch, Hiltrud
    CANCER RESEARCH, 2017, 77
  • [8] CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients
    Ramirez, Gabriel
    Vital, Marcelo
    Vergara, Carolina
    Carusso, Florencia
    Neffa, Florencia
    Valle, Adriana Della
    Esperon, Patricia
    PERSONALIZED MEDICINE, 2023, : 477 - 483
  • [9] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J. Ruddy
    Stephen D. Desantis
    Rebecca S. Gelman
    Alan H. B. Wu
    Rinaa S. Punglia
    Erica L. Mayer
    Sara M. Tolaney
    Eric P. Winer
    Ann H. Partridge
    Harold J. Burstein
    Breast Cancer Research and Treatment, 2013, 141 : 421 - 427
  • [10] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Ruddy, Kathryn J.
    Desantis, Stephen D.
    Gelman, Rebecca S.
    Wu, Alan H. B.
    Punglia, Rinaa S.
    Mayer, Erica L.
    Tolaney, Sara M.
    Winer, Eric P.
    Partridge, Ann H.
    Burstein, Harold J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (03) : 421 - 427
12345